Clinical Trial Update: Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection Delivery Device [Phase 1]

View source ↗

Summary

Phase 1 trial of an Andes virus DNA vaccine delivered with a needle-free device for prevention of Hantavirus Pulmonary Syndrome completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hantavirus Pulmonary Syndrome

Drugs mentioned

• Andes virus DNA vaccine (Andes virus DNA vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Hantavirus Pulmonary Infection, Immunisation | Phase 1 | Status: COMPLETED | Results posted: 2021-10-14